What is the recommended management of mitral regurgitation, including medical therapy, indications for surgery, prosthetic valve selection, and postoperative follow‑up?

Management of Mitral Valve Regurgitation and Postoperative Care

For severe primary mitral regurgitation, mitral valve repair is the preferred surgical technique when durable results are expected, and surgery is indicated for symptomatic patients with LVEF >30% or asymptomatic patients with LV dysfunction (LVESD ≥45 mm and/or LVEF ≤60%). 1

Medical Therapy

Primary Mitral Regurgitation

Medical therapy plays a limited role in primary MR, as there are no medications that prevent valve degeneration or reduce regurgitation severity. However, specific agents may provide benefit in select scenarios:

• Beta-blockers: Strongest evidence for benefit in asymptomatic patients with moderate to severe primary MR—they reduce MR severity, prevent LV function deterioration, and improve survival 2
• ACE inhibitors/ARBs: Reduce MR severity, particularly in asymptomatic patients 2
• Critical caveat: Vasodilators can paradoxically worsen MR in patients with mitral valve prolapse or hypertrophic cardiomyopathy 2

Secondary (Ischemic) Mitral Regurgitation

All patients require guideline-directed medical therapy (GDMT) as first-line treatment 3:

• Aspirin
• P2Y12 inhibitor (if post-PCI)
• High-intensity statin
• Beta-blockers (carvedilol shows specific benefit in reducing MR severity)
• ACE inhibitor or ARB (sacubitril/valsartan preferred when eligible)
• Mineralocorticoid receptor antagonist (eplerenone/spironolactone) based on LVEF and heart failure status

Important reality check: Despite optimal GDMT, 4-year cardiac mortality remains 43-45% with moderate-to-severe secondary MR versus only 6% with mild MR 3

Surgical Indications

Primary Mitral Regurgitation - Clear Algorithm:

Class I (Must Operate):

1. Symptomatic patients with severe MR and LVEF >30% 1
2. Asymptomatic patients with LV dysfunction: LVESD ≥45 mm OR LVEF ≤60% 1

Class IIa (Should Strongly Consider):

• Asymptomatic patients with severe MR when:
  • Recent-onset atrial fibrillation
  • Pulmonary hypertension (PA systolic pressure >50 mmHg)
  • Progressive LV enlargement (LVESD approaching 40 mm) or declining LVEF (approaching 60%)
  • Repair likelihood >95% and surgical mortality <1% at experienced center 4

Secondary Mitral Regurgitation:

Surgery is indicated when severe secondary MR is present in patients undergoing CABG with LVEF >30% 1

For isolated secondary MR: Transcatheter edge-to-edge repair (TEER) has emerged as Class I recommendation for highly selected patients with ventricular secondary MR who remain symptomatic despite optimal GDMT 5

Prosthetic Valve Selection

The choice between mechanical and bioprosthetic valves follows a patient-centered decision tree 1:

Choose Mechanical Valve When:

• Patient desires it after informed discussion AND no contraindication to anticoagulation
• Patient at risk for accelerated structural valve deterioration (young age, renal failure, hyperparathyroidism)

Choose Bioprosthetic Valve When:

• Patient preference after informed discussion
• Anticoagulation contraindicated or unlikely to be maintained (bleeding risk, compliance concerns, lifestyle/occupation factors)
• Reoperation for mechanical valve thrombosis despite good anticoagulation control

Postoperative Management

Mechanical Prostheses:

• Lifelong vitamin K antagonist (VKA) anticoagulation is mandatory 1
• INR self-management recommended with proper training 1
• NOACs are contraindicated 1
• Bridging with therapeutic UFH or LMWH required when VKA interrupted 1

Bioprosthetic Valves:

• Anticoagulation required lifelong only if other indications exist (atrial fibrillation, prior thromboembolism) 1
• Monitor for structural valve deterioration with serial echocardiography
• VKA and/or UFH recommended for bioprosthetic valve thrombosis before considering reintervention 1

Prosthetic Valve Dysfunction - Reintervention Indications:

Urgent/emergency valve replacement indicated for 1:

• Obstructive thrombosis in critically ill patients without serious comorbidity
• Mechanical valve with intractable hemolysis or heart failure from severe prosthetic/paravalvular regurgitation 6

Surgery reasonable for 6:

• Severe symptomatic or asymptomatic bioprosthetic regurgitation
• Paravalvular leak causing hemolysis requiring repeated transfusions or severe symptoms 1

Percutaneous repair of paravalvular regurgitation is reasonable in selected high-risk surgical patients 6

Critical Assessment Pitfalls

Avoid intraoperative MR assessment: Anesthesia causes ventricular unloading that artificially reduces MR severity. Grade MR with patient awake, alert, and medically stable 3

Use integrative approach: Incorporate multiple Doppler parameters rather than relying on single measurements to minimize inherent limitations of each technique 3

TEE essential for mitral prostheses: TTE inadequately visualizes the left atrial side due to acoustic shadowing; TEE provides superior assessment of paravalvular regurgitation 6

Multidisciplinary Heart Team Requirement

All patients with severe valvular disease being considered for intervention must be evaluated by a multidisciplinary team, with referral to or consultation with a Primary or Comprehensive Valve Center 7. This is non-negotiable for optimal outcomes, particularly when choosing between surgical repair, replacement, or transcatheter options.